Aims: To determine, using published general practice-level data, how differences in Type 2 diabetes mellitus (T2DM) prescribing patterns relate to glycaemic target achievement levels. Results: Overall, HbA1c outcomes were not different between the years studied. Although, in percentage terms, most practices increased their use of sodium-glucose co-transporter-2 (SGLT2) inhibitors (96%), dipeptidyl peptidase-4 (DPP-4) inhibitors (76%) and glucagon-like peptide 1 (GLP-1) analogues (53%), there was wide variation in the use of older and newer therapies. For example, 12% of practices used >200% of the national average for some newer agents. In cross-sectional analysis, greater prescribing of metformin and analogue insulin were associated with a higher proportion of patients achieving HbA1c ≤58 mmol/mol; the use of SGLT2 inhibitors and metformin was associated with a reduced proportion of patients with HbA1c >86 mol/mol; otherwise associations for sulphonylureas, GLP-1 analogues, SGLT2 inhibitors and DPP-4 inhibitors were neutral or negative. In year-on-year analysis there was ongoing deterioration in glycaemic control, which was offset to some extent by increased use of SGLT2 inhibitors and GLP-1 analogues, which were associated with a greater proportion of patients achieving HbA1c levels ≤58 mmol/mol and a smaller proportion of patients with HbA1c levels >86 mmol/mol. SGLT2 inhibitor prescribing was associated with significantly greater improvements than those found for GLP-1 analogues.
trations ≤58 mmol/mol (7.5%) fell from 66.5% to 65.7%, 2 whilst the number of people at high glycaemic risk (HGR) with HbA1c >10.0%
(86 mmol/mol) decreased from 7.0% to 6.7%.
These observations raise the important question of whether the increased investment in the newer T2DM therapies can deliver benefits in the real world. The aim of the present study was to determine whether practice-level differences in use of the individual medication classes related to the proportions of people with T2DM achieving TGC or being at HGR.
We investigated whether general practice-level data for England and NDA data on HbA1c outcomes, along with other epidemiological and service indicators for the years 2014 to 2016, were associated with rates of prescribing among the various classes of T2DM medications using a validated approach for combining large datasets. 3, 4 Our aim was to determine, using published general practice-level data, how differences in T2DM prescribing patterns relate to glycaemic target achievement levels. We have described our approach in previous recently published papers. Institute for Health and Care Excellence (NICE) clinical guideline categories operational from 2010 to 2016, including HbA1c ≤58 mmol/ mol (7.5%) and HbA1c ≤86 mmol/mol (10.0%). In the present study, patients achieving HbA1c concentrations ≤7.5% (58 mmol/mol) were defined as achieving TGC and those with HbA1c concentrations >10% (86 mmol/mol) were considered to be at HGR.
Data from general practices in England that participated in 2014/2015 and 2015/2016 were included; however, to minimize outlier effects, practices that reported <100 patients with T2DM on their practice register were excluded.
The monthly general practice prescribing data reports 5 The levels of medication use in each general practice were established for each class according to the ratio of the total DDD to the number of patients on the T2DM register (DDD/T2DM register). The number of T2DM patients on insulin or the number using blood glucose meter (BGM) strips were not directly available, so we calculated these by deducting the estimated amount of insulin and number of BGM strips used by patients with T1DM based on the daily levels of 50 units of insulin and four BGM test strips recommended by NICE, 9 from the total insulin and BGM strips used, assuming the remainder were used by patients with T2DM at a rate of 100 units insulin/day and 1 BGM test strip/day. 10 This number was then shown as a percentage of the T2DM population. Insulin analogue use was expressed as a percentage of total insulin.
The relationships between practice characteristics, prescribing, and glycaemic outcomes (TGC, HGR) were examined both cross- Because of the structure of the data, there was no information concerning the number of patients who managed their condition with diet and lifestyle only, or for whom combinations of multiple therapies were used.
| Patient involvement
No patients, service users, carers or lay people were involved in the design or conduct of this study, which only used publically available data. The outcome measures were derived from NICE standards. The development of the research question and outcome measures were informed by patients' priorities and experience in the everyday clinical setting. Stepwise regression was used to remove the indicators with the highest P values sequentially from the model, until a set with P values all <.01 was reached. The 17 core indicator variables (Table 1) were reduced to 13 for both TGC and HGR for the cross-sectional analysis and to 7 for TGC and 6 for HGR for the longitudinal analysis.
| Analysis
The overall impact of longitudinal changes in prescribing on the changes in outcomes was assessed by applying the calculated linear regression factors to the changes in indicator values for each selected factor. Using the total number of people with T2DM in England as a denominator (2.8 million individuals), the annual average change in indicator value (DDD for medication) and the regression coefficient were applied to the total T2DM population to give an indication of the impact of that indicator on the TGC and HGR outcomes. The inverse of the regression coefficient was used to provide an approximation of the number needed to treat (NNT) to achieve one change in outcome.
The present study was not funded by any external agencies and the analysis used only publicly available grouped data; therefore, ethical approval was not sought.
3 | RESULTS thresholds are used in the QOF from those in the NDA). All these were within AE2% of the overall average figure. This suggests that, apart from size, the UK practices that took part in the NDA were broadly representative of all the general practices in England.
| Practice characteristics
The data for the 3762 practices that completed both years in the NDA showed a decline in local service indicators; for example, the rate of completion of the eight NICE care processes fell from 57.5%
to 53.9% (a relative reduction of 6.5%) and the proportion of patients with BP ≤140/80 mm Hg fell from 74.3% to 73.7% (a relative reduction of 0.8%).
| Variation between practices
There was wide practice-level variation in the use of therapies, as measured by DDD per patient with T2DM. Figure 2A shows the distribution of the relative levels of use of the principally prescribed agents. The x-axis shows the variation around the national mean for prescribing by general practices, while the y-axis shows the proportion of practices at each 5th centile of prescribing of each agent.
Application of medication varied considerably by class across the practices. In the present study, it was measured by the proportion of practices falling within AE30% of the overall mean for each drug class.
Metformin was the most consistently used. The DDD/T2DM register mean ratio was 0.514 and 95% of practices fell within AE30% of this.
Sulphonylureas were the most widely used agent, with a DDD/T2DM register mean of 0.65, but with significantly more variation, with only 62% of practices falling within AE30% of the mean. There was a decline in use of the thiazolidinedione pioglitazone, which had a mean DDD/T2DM register of 0.035 and even more variation in prescribing, with only 26% of practices falling within AE30% of the mean.
While the use of newer agents has been increasing, it remained small, with an overall DDD/T2DM register mean of 0. IMD, index of multiple deprivation; SGLT2, sodium-glucose co-transporter-2; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TGC, target glycaemic control; TZD, thiazolidinedione.
With newer agents, and also with pioglitazone, there were significant practice outliers, with 4% to 14% of practices using >200% of the overall mean and 1% to 5% of practices not using them at all. In contrast, the use of more recently introduced medications increased, with 96% of practices increasing their use of SGLT2 inhibitors (overall national increase 62%), 76% of practices increasing their use of DPP-4 inhibitors (overall increase 11%) and 53% of practices increasing their use of GLP-1 analogues (overall increase 3%). 
| Year-on-year prescribing change

| Cost impact of changes
| Impact of prescribing changes on outcomes
Assuming that changes in prescribing are linked causatively to changes in glycaemic outcomes, Table 2 
| DISCUSSION
Previously, we used cross-sectional analysis within a 2-year period to assess the impact of practice epidemiology, local services and major medications on glucose control in T2DM. 4 This follow-on study, using the latest published practice-level NDA and prescribing data, confirms those findings and uses longitudinal year-on-year analysis to assess the impact of the more recent medications, specifically SGLT2 inhibitors, DPP-4 inhibitors and GLP-1 analogues.
We found that SGLT2 inhibitors and GLP-1 analogues were associated with a greater proportion of patients achieving HbA1c
≤58 mmol/mol; SGLT-2 inhibitor prescribing was associated with greater improvements in HGR than those found for GLP-1 analogues in year-on-year analysis. inhibitor use was associated both with an increase in those achieving TGC and a decrease in those at HGR. The estimated NNT to bring one person into TGC was 5 and to take one person out of HGR was 8. This is in keeping with the EMPA-REG Outcome Study 10 and was the most beneficial association identified. However, despite increased use and increased spend on newer therapies, for which there is clinical trial and real-world evidence of effectiveness, the overall scorecard was balanced rather than improved, with the proportion of patients achieving TGC falling by 0.8% and the proporation at HGR falling by 1.9%. This accords with health economic analysis in the United States.
11
It is recognized that only a relatively small proportion of the variance in glycaemia is accounted for in these analyses. The major factor is the inexorable progression of dysglycaemia year-on-year, which was possibly related to changes in population characteristics such as age (younger), duration (longer) and lifestyle. 12 The small variance in prescribing of metformin across the general practices that took part in the NDA 13 and the progressive decline in pioglitazone use despite its clinical efficacy 14 are not surprising in relation to acknowledged prescribing trends in the United Kingdom.
Previously, we showed through cross-sectional analysis, which we confirmed in this paper, that moving levels of local service performance and prescribing of metformin and sulphonylureas from the median to the 90th percentile level might be associated with 2 10 000 additional patients achieving TGC and 62 000 fewer at HGR. The associations between change in SGLT2 inhibitor and DPP-4 inhibitor prescription at a practice level and the proportions of patients achieving TGC and at HGR may be important, if the link is causative. 15 Improving glucose control by using new drugs would be costly, although the present findings suggest, for example, that an investment of £50 m in additional SGLT2 inhibitors in those practices prescribing around or below the national average level would include an additional 1 00 000 patients and could bring as many as 12 500
patients out of HGR and 20 000 into TGC.
The present study has some limitations. Because of the structure of the data, there was no information concerning the number of patients who were only treated by diet and lifestyle modification or for whom combinations of multiple therapies were used.
In addition, the number of general practices in 2014/2015 was lower than in 2015/2016; however, the number of practices compared year-on-year is sufficient for valid and nationally relevant conclusions to be drawn. We accept that there is a lack of precise information in this study on time span between exposure and outcome. We have recently also described this in relation to (different) treatment variables in people with T1DM using a similar methodology. 16 In the present study, we have focused on glycaemic outcomes.
Prescribing should also take into account many other factors, including patient reaction, patient tolerance and drug side effects.
Results from clinical trials have shown that drugs that lowered HbA1c to similar levels had different effects on patient outcomes. 17, 18 The link between diabetes treatment drug and cardiovascular disease/mortality as an outcome would have to include another set of practice variables, including their use of cardiovascular medication as well as cardiovascular events and mortality, with inclusion of Hospital Episode Statistics data. This will be the subject of future work.
In conclusion, we have shown that greater prescribing of the newer therapies is associated at practice level with more patients achieving target HbA1c (improved TGC outcome) and fewer patients with high-risk HbA1c (improved HGR outcome). At the same time, at a national level, fewer patients are achieving TGC, although there are also fewer patients at HGR. We suggest that SGLT inhibitors, the latest class of oral hypoglycaemic agent, must be considered earlier rather than later in the treatment pathway for individuals with T2DM.
